How did Voyager Therapeutics' revenue and expenses shift in Q4 2024?

Voyager Therapeutics experienced a slight increase in revenue and maintained its R&D and administrative expense levels in Q4 2024 compared to the previous quarter. 1. **Revenue Shift**: - Voyager Therapeutics reported a revenue of $80 million for Q4 2024, which is a notable figure considering the previous quarter’s revenue was $73.72 million. This indicates a growth of approximately 8.54% in revenue. - The company's collaboration revenue contributed significantly to this growth, with $8.99 million allocated for selling, general, and administrative expenses. 2. **Expense Shift**: - The Cost of Goods Sold (COGS) for Q4 2024 was $3.28, which is a slight increase of 0.92% from the previous quarter. This suggests that the cost of producing and delivering the company's goods or services has risen marginally. - Research and Development (R&D) expenses remained stable at $35.58 million, indicating that the company continued to invest heavily in innovation and drug development. - General and Administrative (G&A) expenses also remained stable at $8.99 million, implying that the company's administrative operations did not significantly change during the quarter. In conclusion, Voyager Therapeutics saw a positive shift in revenue, while maintaining stable R&D and G&A expenses in Q4 2024, reflecting the company's focus on growth and continued investment in its core activities.